Benlysta (belimumab) prior authorization for SLE and biopsy‑proven lupus nephritis
Customize your policy alerts
Sign up for all careoregon policy alerts
Know when careoregon releases new policies or updates existing guidance.
Monitor payer policy activity
Prior authorization criteria for use of belimumab (Benlysta) for systemic lupus erythematosus (SLE) and biopsy‑proven lupus nephritis, covering initial and reauthorization requirements and prescriber qualifications for CareOregon members.
No material clinical or coverage changes in this revision.
Coverage and Medical Necessity Criteria
Initial Therapy - Lupus Nephritis
Covered when ALL of the following are met:
from chunks 3 and 4
Reauthorization - Lupus Nephritis
Covered when ALL of the following are met:
from chunks 4 and 5
Initial Therapy - SLE
Covered when ALL of the following are met:
from chunks 6-8
Reauthorization - SLE
Covered when ALL of the following are met:
from chunks 9 and 10
Requests for belimumab for either systemic lupus erythematosus or biopsy‑proven lupus nephritis must not propose concurrent use with another lupus‑specific therapy. Specifically, treatment will not be used with another lupus‑specific treatment (belimumab, anifrolumab, or voclosporin), per the approval criteria for lupus nephritis, and the reauthorization criteria for SLE and lupus nephritis. This exclusion applies whether the other product is a targeted lupus agent or another biologic.
Per the guideline for systemic lupus erythematosus, use of belimumab concurrently with other lupus‑specific treatments or biologics is not permitted. The policy explicitly lists concurrent therapy with belimumab, anifrolumab, or voclosporin (or any biologic) as a disallowed combination when assessing approval and reauthorization requests.
Prior Authorization Requirements and Provider Responsibilities
Prior authorization required for belimumab (Benlysta)
Prior authorization is required for benlysta (belimumab) when used to treat systemic lupus erythematosus (SLE) and biopsy-proven lupus nephritis. Initial approvals are for 6 months; reauthorizations for either indication are listed as 12 months with specified continuation criteria.
Required prior therapy (step therapy)
Member must have tried and failed, or have a documented contraindication to, standard therapies before benlysta will be approved. For SLE this includes failure of corticosteroids, hydroxychloroquine, and immunosuppressants (examples listed). For lupus nephritis the member must have tried and failed or have a contraindication to obinutuzumab.
- SLE: failure of corticosteroids, hydroxychloroquine, and immunosuppressants (e.g., cyclophosphamide, cyclosporine, tacrolimus, leflunomide, azathioprine, mycophenolate, methotrexate) ([[source]] cited).
- Lupus nephritis: tried and failed or contraindication to obinutuzumab.
Required documentation to support prior authorization
Submit documentation that confirms the diagnosis and prior treatment history and demonstrates response or failure to prior therapies. For lupus nephritis, provide biopsy confirmation (Class III, IV, and/or V). Include current standard therapy, prior treatment failures or contraindications, and objective response measures (e.g., stabilized eGFR for LN; reduction in SELENA‑SLEDAI or BILAG scores for SLE).
- Biopsy report confirming lupus nephritis Class III, IV, and/or V (for LN requests).
- Records of prior medication trials and failures or documented contraindications.
- Objective measures of response: stabilized eGFR, reduction in SELENA‑SLEDAI or BILAG index, decreased corticosteroid dose, or fewer exacerbations.
Triggers for denial
Requests may be denied if they do not meet prescriber specialty, diagnostic, or co-therapy requirements. Specifically, denials may occur when the request is not from or in consultation with a rheumatologist or nephrologist, lacks biopsy-proven lupus nephritis for the LN indication, or proposes concurrent use with another lupus-specific treatment or biologic.
- Prescriber is not a rheumatologist or nephrologist and no consultation is documented.
- Lack of kidney biopsy confirming Class III, IV, and/or V lupus nephritis for LN requests.
- Proposed concurrent use with another lupus-specific treatment (belimumab, anifrolumab, or voclosporin) or other biologic.
Key Definitions and Clinical Terms
Background and Drug Information
Belimumab (Benlysta) is an approved therapy for systemic lupus erythematosus and is included in this prior authorization guideline for both SLE and biopsy‑proven lupus nephritis. The policy requires specialist involvement (rheumatologist and/or nephrologist as appropriate), documentation of prior standard therapy trials or contraindications, evidence of treatment response for reauthorization, and specifies initial and reauthorization approval lengths.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.